type 2 diabetese
Conditions
Interventions
A:isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected subcutaneously 30 minutes pre-meal plus acarbose (Bayer) 50mg, 1/noon
B:isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected subcutaneously 30 minutes pre-meal plus acarbose (Bayer) 50mg, 3/day
C:isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected immediately pre-meal plus acarbose (Bayer) 50mg, 3/day.
Sponsors
Department of Geriatrical Endocrinology, Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Type 2 diabetes diagnosed in accordance with WHO criteria 1999 more than six months, age>=60 years old; glycemic control is still not satisfied for having been using insulin therapy more than 3 months (fasting plasma glucose>=7mmol/l and/or 2-hour postprandial plasma glucose>=10mmol/l, and/or HbA1c>=6.5%).
Exclusion criteria
Exclusion criteria: patients with known cancer; patients allergic to insulin or acarbose; serious systemic disease, acute complications of diabetes within 6 months; patients with poor compliance, the researchers consider the patient is not suitable to participate in the observation or who will affect the results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood glucose; | — |
Countries
China
Contacts
Public ContactLi Chunlin
Outcome results
None listed